Paddington Life Sciences Partners is a key driver of the Paddington Life Sciences development led by Imperial.
NWLP has agreed to work together with the other 16 Paddington Life Sciences Partners to improve health and reduce inequalities through four key areas of focus: social value, diversity and equity in clinical trials, data and digital, and place and space.
As an associate member of Paddington Life Sciences Partners, NWLP will have a strategic advisory role and will also support specific projects by bringing in their expertise and insights from diagnostic innovation.
Saghar Missaghian-Cully, Managing Director, said: “We are very excited for NWLP to be part of this partnership. Paddington Life Sciences Partners constitutes a formidable alliance comprising NHS entities, industry leaders, community representatives, and academic institutions, all united by a common dedication to the community of Paddington and its much broader reach.”
Dr Suki Balendra, Director of strategic partnerships for Paddington Life Sciences, said: “North West London Pathology is a fantastic example of how services can be strengthened through partnerships. We are really thrilled that NWLP are bringing their expertise and insights into our work with a focus on our data and digital workstream and beyond.”
Paddington Life Sciences Partners are: British Land, Brockton Everlast, Derwent London, Imperial College Healthcare NHS Trust, Imperial College London, IQVIA, Microsoft, Optum, Oracle Health, Takeda, The Paddington Partnership, Vertex and Vodafone. The Associate Partners are: Imperial College Health Partners, Imperial Health Charity and Healthcare Central London.